Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.

ABSTRACT:

Background

Treatment guidelines recommend LDL-C as the primary target of therapy in patients with hypercholesterolemia. Moreover, combination therapies with lipid-lowering drugs that have different mechanisms of action are recommended when it is not possible to attain LDL-C targets with statin monotherapy. Understanding which treatment or patient-related factors are associated with attaining a target may be clinically relevant.

Methods

Data were pooled from two multicenter, randomized, double-blind studies. After stabilization on simvastatin 20 mg, patients with coronary heart disease (CHD) alone and/or type 2 diabetes mellitus (T2DM) were randomized to ezetimibe 10 mg/simvastatin 20 mg (EZ/Simva) or simvastatin 40 mg. The change from baseline in low-density lipoprotein chol

SUBMITTER: Rotella CM 

PROVIDER: S-EPMC2918617 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature